Michele Samaja
Giuseppina Milano- 1Department of Health Science, University of Milan, Milan, Italy
- 2Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
A condition with inadequate oxygen supply to the tissues, hypoxia plays a pivotal role in the pathology of cyanotic congenital heart defects and several adult diseases as myocardial infarction, stroke, cancer, diabetes, aging, and pulmonary obstruction. Most cell responses to hypoxia are modulated by hypoxia-inducible factors [HIFs (1)], DNA-binding transcription factors that mediate hypoxia adaptation through activation of a multitude of genes encoding proteins needed to improve tissue oxygen delivery, energy metabolism, efficient management of hypoxia-induced stress and regulation of apoptosis, autophagy, and cell cycle. The reoxygenation that follows hypoxia usually induces bursts of reactive oxygen species, which not only cause the oxidative damage central in the pathophysiology of hypoxia/reoxygenation (HReox) injury but also activate signaling mechanisms that in part synergize and in part oppose those induced by hypoxia. Consequently, it becomes often difficult to distinguish what is attributable to hypoxia and what to the reoxygenation that follows hypoxia. A new research frontier may foster clues to understand the mechanisms underlying HReox injury and to identify appropriate targets to design interventions aimed at reducing the toll of this injury in several diseases.
One example is paradigmatic. For many years, hypoxia was believed to be associated with cardioprotection. However, it is now evident that it is not hypoxia, but HReox, the factor providing cardioprotection (2), or hypoxic preconditioning (3). In hearts exposed to hypoxia, alterations in several signaling paths (4, 5) converge into deleterious phenotypes as right ventricular hypertrophy and impaired ability to resist ischemia/reperfusion (6). These findings are corroborated by the clinical observation that the outcome of surgery for repair of cyanotic congenital heart defects is complicated by myocardial damage due to HReox at the moment of the institution of cardiopulmonary bypass with elevated oxygen content, followed by ischemia/reperfusion injury when heart is arrested to perform the intra-cardiac repair (7). HReox is related to the intermittent hypoxia (IH) paradigm, e.g., repeated exposure to short periods of hypoxia 5–10 times/day. Although displaying protective features in the favor of musculoskeletal, pulmonary, central nervous, and cardiopulmonary systems (8), IH may have Janus-like features (9): on the one hand, IH is a form of hypoxic preconditioning (10); on the other hand, it may become dangerous and pave the road to obstructive sleep apnea syndrome (OSAS) (11, 12), which causes harmful redox stress (13).
The purpose of this “Research Topic,” attracting articles dealing with causes and effects of HReox, aims at better understanding the underlying pathophysiology and mechanism in the cardiopulmonary system to improve the outcome of clinical management in several classes of pediatric and adult patients.
Verges et al. (14) reviewed if and how hypoxic preconditioning is a valid therapeutic modality in healthy subjects (hematology, ventilation, cardiovascular system, and metabolic status) and in patients affected by cardiovascular (acute myocardial infarction, chronic coronary artery disease, heart failure), neurological (stroke, spinal cord injury), respiratory (OSAS, chronic obstructive pulmonary diseases), and metabolic diseases. It appears that hypoxic preconditioning, or IH training, is distinguishable from dangerous OSAS-like IH essentially for intensity and frequency of hypoxia challenges. Indeed, the progression from protective to dangerous IH is a continuum based on intensity and physical characteristic of the HReox spikes. A role for CO2 handling is envisaged because, whereas protective IH is characterized by hypocapnic hypoxemia, OSAS-like IH is characterized by hypercapnic hypoxemia. In both cases, the molecular determinants for the cell response to HReox are primarily HIFs followed by HIF downstream responses involving GATA-4, K+ channels, various MAPK, EPO, and the PI3K/Akt pathways.
Serebrovskaya and Xi (15) started from the concept that IH might occur in early infancy in both preterm and term infants, and 2–4% of all children are affected by OSAS. There are numerous reports indicating adverse effects of IH on development, behavior, achievement, and cognition in OSAS children, although the exact causative relationship remains uncertain. On the other hand, well-controlled and moderate IH can be used in sick children for treating various forms of bronchial asthma, allergic dermatoses, autoimmune thyroiditis, cerebral palsy, and obesity. The review into the critical role of IH in childhood and comparison of the genesis of harmful vs. beneficial effects of IH leads to emphasize the dual aspect of IH leading to hypoxia preconditioning and OSAS-like IH. Not only CO2 handling but also hypoxia-induced polycythemia are identified as most important determinants for the divergent effects of these two paradigms.
Hashimoto and Shibasaki (16) clarified the role of HIFs in regulating the transcription of genes that mediate the response to hypoxia, especially in carcinogenesis and in the pathology of ischemic diseases. Unexpectedly, clinical trials targeted at the control of therapeutic angiogenesis after the administration of a single growth factor have yielded unsatisfactory or controversial results for a range of causes accurately examined in their review. However, the manipulation of HIF-2α, which plays an essential role in vascular remodeling, appears more promising for the treatment of ischemic diseases caused by arterial obstruction, where insufficient development of collateral vessels impedes effective therapy. Indeed, the eukaryotic initiation factor 3 subunit e (eIF3e)/INT6 has been identified as the molecular target that stabilizes specifically HIF-2α even under normoxia, thereby inducing the expression of several angiogenic factors, and reducing injury in ischemic limbs or cold-injured brains in animal models.
Farah and Reboul (17) focused into a most prominent factor in IH-downstream pathway, e.g., nitric oxide (NO). They describe the characteristics of the various NO synthase isoforms in providing NO, and the ways by which NO exerts its effects against I/R injury, through activation of the guanylate cyclase and protein kinase G pathway, or through S-nitrosylation of certain proteins. This view of the phenomenon related to the protective vs. harmful effects of NO opens a more rational understanding of the contribution and importance of NO with respect to the subcellular localization (especially with reference to sarcoplasmic reticulum and mitochondrial proteins), concentration (NO bioavailability may be considered advantageous below a threshold level but harmful above it), and timing (thus opening an interesting window for oral-based nitrite therapies to prevent I/R injury).
Wellmann et al. (18) described how both hypoxia and hyperoxia trigger focal necrosis in brain white matter giving raise to diffuse white matter diseases, and consequently disturb myelination in newborn infants during a critical developmental window prior to the onset of myelination. This may represent the underlying cause for an array of cognitive and behavioral diseases. Using various targeted experimental models, it has been shown that the molecular basis of such phenotypes, e.g., HIF-1α and HIF-2α, can be activated by both hypoxia (through the canonical β-catenin-Wnt signaling) and paradoxically by a situation that resembles hyperoxia (transgenic embryonic mice unable to express HIF-1α and HIF-2α). Such findings emphasize the importance of avoiding extremes of oxygen tension in the brains of preterm infants and in infants with congenital heart disease undergoing surgery.
In summary, these reviews converge into the view that appropriate management of HReox may help curing many diseases and may provide pediatric surgeons valuable tools to reduce hypoxia-induced complicacies (2, 19).
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. Proc Natl Acad Sci U S A (1991) 88:5680–4. doi: 10.1073/pnas.88.13.5680
2. Milano G, Corno AF, Lippa S, Von Segesser LK, Samaja M. Chronic and intermittent hypoxia induce different degrees of myocardial tolerance to hypoxia-induced dysfunction. Exp Biol Med (Maywood) (2002) 227:389–97.
3. Shizukuda Y, Mallet R, Lee S, Downey H. Hypoxic preconditioning of ischaemic canine myocardium. Cardiovasc Res (1992) 26:534–42. doi:10.1093/cvr/26.5.534
4. Milano G, Bianciardi P, Corno AF, Raddatz E, Morel S, von Segesser LK, et al. Myocardial impairment in chronic hypoxia is abolished by short aeration episodes: involvement of K+ATP channels. Exp Biol Med (Maywood) (2004) 229:1196–205.
5. Morel S, Milano G, Ludunge KM, Corno AF, Samaja M, Fleury S, et al. Brief reoxygenation episodes during chronic hypoxia enhance posthypoxic recovery of LV function: role of mitogen-activated protein kinase signaling pathways. Basic Res Cardiol (2006) 101:336–45. doi:10.1007/s00395-006-0596-1
6. Caretti A, Morel S, Milano G, Fantacci M, Bianciardi P, Ronchi R, et al. Heart HIF-1alpha and MAP kinases during hypoxia: are they associated in vivo? Exp Biol Med (Maywood) (2007) 232:887–94.
7. Corno AF, Milano G, Samaja M, Tozzi P, von Segesser LK. Chronic hypoxia: a model for cyanotic congenital heart defects. J Thorac Cardiovasc Surg (2002) 124:105–12. doi:10.1067/mtc.2002.121302
8. Samaja M, Veicsteinas A, Milano G. Effects of intermittent versus chronic hypoxia on myocardial ischemic tolerance. In: Xi L, Serebrovskaya TV, editors. Intermittent Hypoxia, From Molecular Mechanisms to Clinical Applications. New York, NY: Nova Science Publishers, Inc (2010). p. 19–52.
9. Bassovitch O. Intermittent hypoxic training: risks versus benefits. A biomedical engineering point of view. Eur J Appl Physiol (2010) 110:659–60. doi:10.1007/s00421-010-1522-7
10. Roels B, Bentley DJ, Coste O, Mercier J, Millet GP. Effects of intermittent hypoxic training on cycling performance in well-trained athletes. Eur J Appl Physiol (2007) 101:359–68. doi:10.1007/s00421-007-0506-8
11. Monneret D, Tamisier R, Ducros V, Garrel C, Levy P, Baguet JP, et al. The impact of obstructive sleep apnea on homocysteine and carotid remodeling in metabolic syndrome. Respir Physiol Neurobiol (2012) 180:298–304. doi:10.1016/j.resp.2011.12.009
12. Chamberlin NL, Ling L. The effect of intermittent hypoxia on obstructive sleep apnea: beneficial or detrimental? J Appl Physiol (2011) 110:9–10. doi:10.1152/japplphysiol.01191.2010
13. Inagi R. Inhibitors of advanced glycation and endoplasmic reticulum stress. Methods Enzymol (2011) 491:361–80. doi:10.1016/B978-0-12-385928-0.00020-1
14. Verges S, Chacaroun S, Godin-Ribuot D, Baillieul S. Hypoxic conditioning as a new therapeutic modality. Front Pediatr (2015) 3:58. doi:10.3389/fped.2015.00058
15. Serebrovskaya TV, Xi L. Intermittent hypoxia in childhood: the harmful consequences versus potential benefits of therapeutic uses. Front Pediatr (2015) 3:44. doi:10.3389/fped.2015.00044
16. Hashimoto T, Shibasaki F. Hypoxia-inducible factor as an angiogenic master switch. Front Pediatr (2015) 3:33. doi:10.3389/fped.2015.00033
17. Farah C, Reboul C. NO better way to protect the heart during ischemia-reperfusion: to be in the right place at the right time. Front Pediatr (2015) 3:6. doi:10.3389/fped.2015.00006
18. Wellmann S, Buhrer C, Schmitz T. Focal necrosis and disturbed myelination in the white matter of newborn infants: a tale of too much or too little oxygen. Front Pediatr (2014) 2:143. doi:10.3389/fped.2014.00143
Keywords: intermittent hypoxia, hypoxia-inducible factor, hypoxic preconditioning, reoxygenation, OSAS, myocardial ischemia
Citation: Samaja M and Milano G (2015) Editorial – Hypoxia and reoxygenation: from basic science to bedside. Front. Pediatr. 3:86. doi: 10.3389/fped.2015.00086
Received: 15 August 2015; Accepted: 30 September 2015;
Published: 19 October 2015
Edited and reviewed by: Cecile Tissot, The University Children’s Hospital of Geneva, Switzerland
Copyright: © 2015 Samaja and Milano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michele Samaja, bWljaGVsZS5zYW1hamEmI3gwMDA0MDt1bmltaS5pdA==